Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Celldex Therapeutics (CLDX) Stock Price
Media headlines about Celldex Therapeutics (NASDAQ:CLDX) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.554218359895 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at $2.93 on Wednesday. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $4.12.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.07. The company had revenue of $3.90 million during the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. Celldex Therapeutics’s quarterly revenue was up 77.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.29) earnings per share. research analysts expect that Celldex Therapeutics will post -0.93 earnings per share for the current fiscal year.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.